|Table of Contents|

Thrombocytopenia induced by T-DM1 therapy after neoadjuvant therapy of locally advanced HER-2+/HR+ breast cancer:2 cases report and literature review

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2846-2850
Research Field:
Publishing date:

Info

Title:
Thrombocytopenia induced by T-DM1 therapy after neoadjuvant therapy of locally advanced HER-2+/HR+ breast cancer:2 cases report and literature review
Author(s):
HUANG Shangke; FAN Juan; LIU Xiaolong; SONG Xuemei; HE Lijia
Department of Oncology,the Affiliated Hospital of Southwest Medical University,Sichuan Luzhou 646000,China.
Keywords:
HER-2+/HR+ breast cancer; neoadjuvant therapy; T-DM1; refractory grade IV thrombocytopenia; TCbHP
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.15.015
Abstract:
Objective:To investigate the safety of T-DM1 adjuvant intensive therapy for patients after neoadjuvant therapy and the risk factors for thrombocytopenia.Methods:Two patients suffered locally advanced HER-2+/HR+ breast cancer treated with neoadjuvant TCbHP regimen,postoperative pathological non-pCR,and T-DM1 adjuvant intensive therapy with refractory IV degree thrombocytopenia were researched and followed up.The clinical features and comprehensive reasons were analyzed.Results:Both patients belonged to the domestic population,middle-aged and elderly HER-2+/HR+ women,locally advanced patients,received ≥5 consecutive times of carboplatin-containing chemotherapy and adjuvant radiotherapy,had ≥II degree thrombocytopenia during the course of treatment,and received ≥3 consecutive times of T-DM1 treatment.The patient’s bone marrow-producing megakaryocytes were reduced,and the effect of repeated stimulation of the bone marrow was not well.The cumulative time from platelet decline to recovery was more than 5 months.Conclusion:We believe that the T-DM1 adjuvant intensive therapy for locally advanced HER-2+/HR+ breast cancer patients after neoadjuvant therapy can be started at a low dose,or T-DM1 therapy can be started 1 month after adjuvant radiotherapy,which may be tolerated by patients and the treatment safety will be better.

References:

［1］ VON MG,HUANG CS,MANO MS,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer［J］.N Engl J Med,2019,380(7):617-628.
［2］ WEDAM S,FASHOYIN-AJE L,GAO X,et al.FDA approval summary:ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer［J］.Clin Cancer Res,2020,26(16):4180-4185.
［3］ KROP IE,KIM SB,MARTIN AG,et al.Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA):final overall survival results from a randomised open-label phase 3 trial［J］.Lancet Oncol，2017,18(6):743-754.
［4］ VERMA S,MILES D,GIANNI L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer［J］.N Engl J Med,2012,367(19):1783-1791.
［5］ DIRAS V,MILES D,VERMA S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial［J］.Lancet Oncol,2017,18(6):732-742.
［6］ HURVITZ SA,MARTIN M,SYMMANS WF,et al.Neoadjuvant trastuzumab,pertuzumab,and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE):a randomised,open-label,multicentre,phase 3 trial［J］.Lancet Oncol,2018,19(1):115-126.
［7］ 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)［J］.中国癌症杂志,2021,31(8):770-856.Chinese Anti-Cancer Association,Committee of Breast Cancer Society.Guidelines and norms for diagnosis and treatment of breast cancer of China anti-cancer association (2021 edition)［J］.China Oncology,2021,31(8):770-856.
［8］ VAN RAMSHORST MS,VAN DER VOORT A,VAN WERKHOVEN ED,et al.Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2):a multicentre,open-label,randomised,phase 3 trial［J］.Lancet Oncol,2018,19(12):1630-1640.
［9］ KROP IE,IM SA,BARRIOS C,et al.Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer:the phase III KAITLIN study［J］.J Clin Oncol,2022,40(5):438-448.
［10］ MONTEMURRO F,ELLIS P,ANTON A,et al.Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer:primary results from the KAMILLA study cohort 1［J］.Eur J Cancer,2019,109:92-102.
［11］ WUERSTLEIN R,ELLIS P,MONTEMURRO F,et al.Final results of the global and Asia cohorts of KAMILLA,a phase IIIb safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer［J］.ESMO Open,2022,7(5):100561.
［12］ 朱祖懿.中国免疫性血小板减少性紫癜患者中fcγriia、fcγriiia基因多态性及其临床意义初探［D］.北京:北京协和医学院,2009.ZHU ZY.Gene polymorphisms of fcγriia and fcγriiia in Chinese patients with immune thrombocytopenic purpura and their clinical significance［D］.Beijing:Peking Union Medical College,2009.
［13］ LIU F,KE J,SONG Y.T-DM1-induced thrombocytopenia in breast cancer patients:new perspectives［J］.Biomed Pharmacother,2020,129:110407.
［14］ 丁倩,罗璨,周娟.T-DM1导致脑水肿、血小板减少及谷草转氨酶升高1例［J］.世界最新医学信息文摘,2017,17(76):190-191.DING Q,LUO C,ZHOU J.T-DM1 leads to cerebral edema,thrombocytopenia and elevated aspartate aminotransferase in 1 case［J］.World Latest Medicine Information (Electronic Version),2017,17(76):190-191.
［15］ 祁巧玲,俞平,房文通.临床药师参与1例T-DM1致血小板IV度降低及其治疗的案例分析［J］.中国药物应用与监测,2017,16(6):377-379.QI QL,YU P,FANG WT.A case analysis of a grade 4 thrombocytopenia induced by T-DM1 and its treatment participated by clinical pharmacist［J］.Chinese Journal of Drug Application and Monitoring,2017,16(6):377-379.
［16］ 李达学,肖茜,高寒.恩美曲妥珠单抗治疗复发转移性乳腺癌一例并文献复习［J］.中华内分泌外科杂志,2021,15(2):214-216.LI DX,XIAO Q,GAO H.A case report of T-DM1 in treatment of recurrent metastatic breast cancer［J］.Chinese Journal of Endocrine Surgery,2021,15(2):214-216.
［17］ 燕冰雪,黄世芬,夏云霞,等.曲妥珠单抗－美坦新(T-DM1)治疗HER-2 阳性晚期乳腺癌疗效和安全性的 Meta分析［J］.现代肿瘤医学,2021,29(14):2447-2453.YAN BX,HUANG SF,XIA YX,et al.The Meta-analysis of the efficacy and safety of trastuzumab-emtansine (T-DM1) in the treatment of HER-2 positive advanced breast cancer［J］.Modern Oncology,2021,29(14):2447-2453.

Memo

Memo:
西南医科大学附属医院博士科研启动基金（编号：19025）
Last Update: 2023-06-30